Ahmed M. Aribi

Hematology

1500 Duarte Rd
Duarte, CA 91010

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 71 publications

Pediatric-inspired therapy and blinatumomab consolidation improve outcomes in young adults with Philadelphia-like acute lymphoblastic leukemia.

Pediatric-inspired therapy and blinatumomab consolidation improve outcomes in young adults with Philadelphia-like acute lymphoblastic leukemia.

Journal: Haematologica

Published: June 24, 2026

Clinical Implications of CD19-Negative Relapse Following CD19-Directed Therapy in B-Cell Acute Lymphoblastic Leukemia.

Clinical Implications of CD19-Negative Relapse Following CD19-Directed Therapy in B-Cell Acute Lymphoblastic Leukemia.

Journal: American journal of hematology

Published: May 29, 2026

Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Versus-Host Disease and Nonrelapse Mortality After Allogeneic Transplantation.

Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Versus-Host Disease and Nonrelapse Mortality After Allogeneic Transplantation.

Journal: Transplantation and cellular therapy

Published: May 01, 2026

CAR T Cell Therapy as a Definitive Consolidation for Older Adults with B-ALL in First Complete Remission.

CAR T Cell Therapy as a Definitive Consolidation for Older Adults with B-ALL in First Complete Remission.

Journal: Blood advances

Published: May 01, 2026

CAR T-cell therapy as a definitive consolidation for older adults with B-ALL in first complete remission.

CAR T-cell therapy as a definitive consolidation for older adults with B-ALL in first complete remission.

Journal: Blood advances

Published: May 01, 2026

A phase 1 trial of CD123-directed chimeric antigen receptor T-cell therapy in adults with relapsed/refractory acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm.

A phase 1 trial of CD123-directed chimeric antigen receptor T-cell therapy in adults with relapsed/refractory acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm.

Journal: Journal of hematology & oncology

Published: March 24, 2026

Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study.

Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study.

Journal: Haematologica

Published: March 20, 2026

Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 11, 2026

Disability-Free Survival: A Novel Morbidity Endpoint for Older Adult Allogeneic Hematopoietic Cell Transplantation.

Disability-Free Survival: A Novel Morbidity Endpoint for Older Adult Allogeneic Hematopoietic Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: January 30, 2026

Efficacy of Splenectomy for Hematologic Malignancies: A Retrospective Cohort Study.

Efficacy of Splenectomy for Hematologic Malignancies: A Retrospective Cohort Study.

Journal: Annals of surgery

Published: January 28, 2026

Current status and future potential of CD123-based targeted therapies for acute leukemia.

Current status and future potential of CD123-based targeted therapies for acute leukemia.

Journal: Expert opinion on biological therapy

Published: December 23, 2025

Hypomethylating agents-venetoclax as salvage therapy for relapse of AML and MDS after allogeneic HCT.

Hypomethylating agents-venetoclax as salvage therapy for relapse of AML and MDS after allogeneic HCT.

Journal: Blood neoplasia

Published: December 19, 2025

Showing 1-12 of 71

Last Updated: 09/26/2026